Foreign-Trade Zone 7 - - Mayaguez, Puerto Rico, Application for Temporary/Interim Manufacturing Authority, Merck Sharpe & Dohme Quimica De Puerto Rico, Inc., (Pharmaceutical Products), Caguas, Puerto Rico, 27801 [E7-9539]
Download as PDF
Federal Register / Vol. 72, No. 95 / Thursday, May 17, 2007 / Notices
pwalker on PROD1PC71 with NOTICES
Comment Requested
This notice of intent initiates the
scoping process which guides the
development of the environmental
impact statement. The Nez Perce
National Forest is seeing comments and
issues you may have regarding this
project. Comments are most useful if
they are specific.
Early Notice of Importance of Public
Participation in Subsequent
Environmental Review: A draft
environmental impact statement will be
prepared for comment. The comment
period on the draft environmental
impact statement will be 45 days from
the date the Environmental Protection
Agency publishes the notice of
availability in the Federal Register.
The Forest Service believes, at this
early stage, it is important to give
reviewers notice of several court rulings
related to public participation in the
environmental review process. First,
reviewers of draft environmental impact
statements must structure their
participation in the environmental
review of the proposal so that it is
meaningful and alerts an agency to the
reviewer’s position and contentions.
Vermont Yankee Nuclear Power Corp. v.
NRDC, 435 U.S. 519,553 (1978). Also,
environmental objections that could be
raised at the draft environmental impact
statement stage but that are not raised
until after completion of the final
environmental impact statement may be
waived or dismissed by the courts. City
of Angoon v. Hodel, 803 F.2d 1016,
1022 (9th Cir. 1986) and Wisconsin
Heritages, Inc. v. Harris, 490 F. Supp.
1334, 1338 (E.D. Wis. 1980). Because of
these court rulings, it is very important
that those interested in this proposed
action participate by the close of the 45
day comment period so that comments
and objections are made available to the
Forest Service at a time when it can
meaningfully consider them and
respond to them in the final
environmental impact statement.
To assist the Forest Service in
identifying and considering issues nd
concerns on the proposed action,
comments on the draft environmental
impact statement should be as specific
as possible. It is also helpful if
comments refer to specific pages or
chapters of the draft statement.
Comments may also address the
adequacy of the draft environmental
impact statement or the merits of the
alternatives formulated and discussed in
the statement. Reviewers may wish to
refer to the Council on Environmental
Quality Regulations for implementing
the procedural provisions of the
VerDate Aug<31>2005
17:15 May 16, 2007
Jkt 211001
National Environmental Policy Act at 40
CFR 1503.3 in addressing these points.
Comments received, including the
names and addresses of those who
comment, will be considered part of the
public record on this proposal and will
be available for public inspection.
(Authority:
40 CFR 1501.7 and 1508.22; Forest
Service Handbook 1909.15, Section 21.)
Dated: May 10, 2007.
Jane L. Cottrell,
Nez Perce National Forest Supervisor.
[FR Doc. 07–2419 Filed 5–16–07; 8:45 am]
BILLING CODE 3410–11–M
DEPARTMENT OF COMMERCE
Foreign–Trade Zones Board
[Docket T–3–2007]
Foreign–Trade Zone 7 - - Mayaguez,
Puerto Rico, Application for
Temporary/Interim Manufacturing
Authority, Merck Sharpe & Dohme
Quimica De Puerto Rico, Inc.,
(Pharmaceutical Products), Caguas,
Puerto Rico
An application has been submitted to
the Executive Secretary of the Foreign–
Trade Zones Board (the Board) by the
Puerto Rico Industrial Development
Company (PRIDCO), grantee of FTZ 7,
requesting temporary/interim
manufacturing (T/IM) authority within
FTZ 7 at the MOVA Pharmaceutical
Corporation (MOVA) facility in Caguas,
Puerto Rico, on behalf of Merck Sharp
& Dohme Quimica De Puerto Rico, Inc.
(MSDQ). The application was filed on
May 10, 2007.
The MOVA facility (650 employees,
250,000 sq. ft.) is located at State Road
1, Km 34.8, within the Villa Blanca
Industrial Park in Caguas (Site 1, Parcel
2). T/IM procedures would be used for
pharmaceutical manufacturing
involving two products, MK–431A and
sitagliptin (HTSUS 3004.90 and
2933.59) on behalf of MSDQ for the U.S.
market and export. Foreign components
that would be used in the
manufacturing process (up to 25% of
total content) include sitagliptin,
metformin hydrochloride, enamine
amide and butyl josphos (duty rates of
3.7 to 6.5%). MSDQ has also submitted
a request for permanent FTZ
manufacturing authority (which will be
docketed with the Board separately).
FTZ procedures would exempt MSDQ
from Customs duty payments on foreign
components used in production for
export to non–NAFTA countries. For
domestic and NAFTA markets, MSDQ
could select the duty rate that applies to
PO 00000
Frm 00002
Fmt 4703
Sfmt 4703
27801
the finished product (duty–free to 6.5%)
for the components used in production
when the finished products are entered
for U.S. consumption from the zone.
The application indicates that the
company would also realize duty
deferral and certain logistical/supply
chain savings.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at the
following address: Office of the
Executive Secretary, Room 2111, U.S.
Department of Commerce, 1401
Constitution Avenue, NW., Washington,
DC 20230. The closing period for receipt
of comments is June 18, 2007.
A copy of the application will be
available for public inspection at the
Office of the Foreign–Trade Zones
Board’s Executive Secretary at the
address listed above. For further
information, contact Christopher Kemp
at: christopherlkemp@ita.doc.gov, or
(202) 482–0862.
Dated: May 10, 2007.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E7–9539 Filed 5–16–07; 8:45 am]
BILLING CODE 3510–DS–S
DEPARTMENT OF COMMERCE
International Trade Administration
[A–201–830]
Carbon and Certain Alloy Steel Wire
Rod from Mexico: Extension of Time
Limits for the Preliminary Results of
Antidumping Duty Administrative
Review
Import Administration,
International Trade Administration,
Department of Commerce.
FOR FURTHER INFORMATION CONTACT:
Jolanta Lawska or John Conniff, AD/
CVD Operations, Office 3, Import
Administration, International Trade
Administration, U.S. Department of
Commerce, 14th Street and Constitution
Ave, NW., Washington, DC 20230;
telephone: (202) 482–8362 or (202) 482–
1009, respectively.
SUPPLEMENTARY INFORMATION:
AGENCY:
Background
On November 27, 2006, the
Department of Commerce
(‘‘Department’’) published a notice of
initiation of the administrative review of
the antidumping duty order on carbon
and certain alloy steel wire rod from
Mexico, covering the period October 1,
2005, to September 30, 2006. See
Initiation of Antidumping and
E:\FR\FM\17MYN1.SGM
17MYN1
Agencies
[Federal Register Volume 72, Number 95 (Thursday, May 17, 2007)]
[Notices]
[Page 27801]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-9539]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[Docket T-3-2007]
Foreign-Trade Zone 7 - - Mayaguez, Puerto Rico, Application for
Temporary/Interim Manufacturing Authority, Merck Sharpe & Dohme Quimica
De Puerto Rico, Inc., (Pharmaceutical Products), Caguas, Puerto Rico
An application has been submitted to the Executive Secretary of the
Foreign-Trade Zones Board (the Board) by the Puerto Rico Industrial
Development Company (PRIDCO), grantee of FTZ 7, requesting temporary/
interim manufacturing (T/IM) authority within FTZ 7 at the MOVA
Pharmaceutical Corporation (MOVA) facility in Caguas, Puerto Rico, on
behalf of Merck Sharp & Dohme Quimica De Puerto Rico, Inc. (MSDQ). The
application was filed on May 10, 2007.
The MOVA facility (650 employees, 250,000 sq. ft.) is located at
State Road 1, Km 34.8, within the Villa Blanca Industrial Park in
Caguas (Site 1, Parcel 2). T/IM procedures would be used for
pharmaceutical manufacturing involving two products, MK-431A and
sitagliptin (HTSUS 3004.90 and 2933.59) on behalf of MSDQ for the U.S.
market and export. Foreign components that would be used in the
manufacturing process (up to 25[percnt] of total content) include
sitagliptin, metformin hydrochloride, enamine amide and butyl josphos
(duty rates of 3.7 to 6.5[percnt]). MSDQ has also submitted a request
for permanent FTZ manufacturing authority (which will be docketed with
the Board separately).
FTZ procedures would exempt MSDQ from Customs duty payments on
foreign components used in production for export to non-NAFTA
countries. For domestic and NAFTA markets, MSDQ could select the duty
rate that applies to the finished product (duty-free to 6.5[percnt])
for the components used in production when the finished products are
entered for U.S. consumption from the zone. The application indicates
that the company would also realize duty deferral and certain
logistical/supply chain savings.
Public comment is invited from interested parties. Submissions
(original and 3 copies) shall be addressed to the Board's Executive
Secretary at the following address: Office of the Executive Secretary,
Room 2111, U.S. Department of Commerce, 1401 Constitution Avenue, NW.,
Washington, DC 20230. The closing period for receipt of comments is
June 18, 2007.
A copy of the application will be available for public inspection
at the Office of the Foreign-Trade Zones Board's Executive Secretary at
the address listed above. For further information, contact Christopher
Kemp at: christopher_kemp@ita.doc.gov, or (202) 482-0862.
Dated: May 10, 2007.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E7-9539 Filed 5-16-07; 8:45 am]
BILLING CODE 3510-DS-S